GlassScriptPhysician profile
Zev Frankel
NPI 1477758670
$3,964.14
in general payments reported to CMS, 2019-2025
29 companies · $130 in 2025
The $130 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,267 · 2020: $294 · 2021: $385 · 2022: $1,068 · 2023: $278 · 2024: $542 · 2025: $130.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $885 · Education: $64.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $885.13 |
| Education | $64.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $482.91 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $379.24 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $324.77 | 2019-2023 | Atacand |
| Boston Scientific Corporation | $308.60 | 2019-2024 | Watchman Flx, Watchman Access System |
| Sanofi-Aventis U.S. LLC | $293.05 | 2019-2023 | |
| Amgen INC. | $267.22 | 2019-2024 | Repatha |
| Abbott Laboratories | $242.32 | 2022-2024 | Cardiomems |
| Boehringer Ingelheim Pharmaceuticals, INC. | $238.37 | 2019-2025 | Jardiance |
| Arbor Pharmaceuticals, INC. | $191.11 | 2019-2021 | |
| Novo Nordisk INC | $190.85 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $172.52 | 2019-2024 | |
| Regeneron Healthcare Solutions, INC. | $131.79 | 2019-2022 | |
| Amarin Pharma, INC. | $131.53 | 2019-2023 | |
| Kowa Pharmaceuticals America, INC. | $111.34 | 2019-2023 | Livalo |
| Merck Sharp & Dohme LLC | $99.25 | 2022-2024 | Verquvo |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cvrx, INC. | $97.48 | 2022-2024 | Barostim Neo System |
| E.R. Squibb & Sons, L.L.C. | $88.14 | 2019-2021 | |
| Gilead Sciences, INC. | $43.07 | 2019 | |
| Kiniksa Pharmaceuticals, LTD. | $27.46 | 2022 | |
| Bardy Diagnostics, INC. | $19.84 | 2020 | |
| Preventice Services, LLC | $17.25 | 2019 | |
| Esperion Therapeutics, INC. | $15.45 | 2021 | |
| Azurity Pharmaceuticals, INC. | $14.54 | 2022 | |
| Kiniksa Pharmaceuticals International, Plc | $13.25 | 2024 | Arcalyst |
| Heartflow, INC. | $13.19 | 2023 | Ffrct |
| Portola Pharmaceuticals, LLC | $13.16 | 2019 | |
| Alnylam Pharmaceuticals INC. | $12.85 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $12.27 | 2019 | |
| Irhythm Technologies, INC. | $11.32 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zev Frankel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.